Search results
Showing 676 to 690 of 2105 results for technology appraisal
Teprotumumab for treating thyroid eye disease (deferred appraisal of D1) [ID6756]
In development Reference number: GID-TA11995 Expected publication date: 08 October 2026
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
We want you to be involved in our work - whether you’re commenting on our draft recommendations, taking part in guidance development or attending a committee meeting, your voice is important to us.
Evidence-based recommendations on tixagevimab plus cilgavimab (Evusheld) for preventing COVID-19 in adults.
Evidence-based recommendations on autologous chondrocyte implantation in people with symptomatic articular cartilage defects of the knee.
This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.
Evidence-based recommendations on dostarlimab (Jemperli) with platinum-containing chemotherapy for primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency in adults.
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
NICE Advice works closely with our system partners and industry to drive innovation into the hands of health and care professionals, to enable best practice.
Our HealthTech Programme evaluates new HealthTech.
Aflibercept for treating choroidal neovascularisation (TA486)
Evidence-based recommendations on aflibercept (Eylea) for treating choroidal neovascularisation in adults.
Obeticholic acid for treating primary biliary cholangitis (TA443)
Evidence-based recommendations on obeticholic acid (Ocaliva) for treating primary biliary cholangitis in adults.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Evidence-based recommendations on dapagliflozin (Forxiga) for treating chronic heart failure with preserved or mildly reduced ejection fraction in adults.
Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]
In development Reference number: GID-HST10069 Expected publication date: TBC